{"id":"W4404025318","doi":"10.1002/oby.24184","title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (<scp>SYNCHRONIZE™</scp>‐1 and ‐2)","year":2024,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); University of Calgary; McMaster University; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim Stiftung","keywords":"Medicine; Tolerability; Type 2 diabetes; Placebo; Obesity; Internal medicine; Clinical trial; Clinical endpoint; Randomization; Diabetes mellitus; Randomized controlled trial; Weight loss; Physical therapy; Adverse effect; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07103197,0.00348107,0.004731808,0.001383486,0.001993356,0.003198863,0.002599986,0.006525998,0.007176936],"category_scores_gemma":[0.03695338,0.002453677,0.004366215,0.001307006,0.003370488,0.00255121,0.001498091,0.00575291,0.00141657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002468057,"about_ca_system_score_gemma":0.00917318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008402762,"about_ca_topic_score_gemma":0.002187891,"domain_scores_codex":[0.9492857,0.04291385,0.002327001,0.001828432,0.002349727,0.001295301],"domain_scores_gemma":[0.9831782,0.006168934,0.004096186,0.002081808,0.00193842,0.002536479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9068098,0.01237661,0.00203233,0.006073709,0.003334548,0.0001531355,0.0003232649,0.001711057,0.005753346,0.00394207,0.006448135,0.05104195],"study_design_scores_gemma":[0.9225093,0.05849715,0.001317038,0.0005781702,0.001287142,0.00007454359,0.0000536224,0.001705182,0.001154977,0.001772268,0.01098543,0.00006521537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.09675599,0.01552061,0.0239442,0.006300176,0.004402454,0.8428913,0.003350663,0.0005614756,0.006273185],"genre_scores_gemma":[0.1140991,0.002666198,0.04986309,0.006175561,0.001213739,0.8229467,0.000688021,0.00008007177,0.002267426],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.07103197,"threshold_uncertainty_score":0.3756574,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1228314826761485,"score_gpt":0.4166436150841353,"score_spread":0.2938121324079868,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}